Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute Coronary Syndrome in a 40-Year-Old Male With Coronary Ectasia: A Case Report.

Cureus·2025
Same author

Disparities in Neonatal Mortalities in the United States.

Children (Basel, Switzerland)·2023
Same author

Coenzyme Q10 for heart failure.

The Cochrane database of systematic reviews·2022
Same author

Cryoballoon vs radiofrequency ablation of atrial fibrillation: insights from the Veterans Healthcare System.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2021
Same author

Haloperidol discontinuation for people with schizophrenia.

The Cochrane database of systematic reviews·2019
Same author

Calcium channel blockers for antipsychotic-induced tardive dyskinesia.

The Cochrane database of systematic reviews·2018
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Coenzyme Q10 for heart failure.

Mohammed E Madmani1, Ahmad Yusuf Solaiman, Khalil Tamr Agha

  • 1Department of internal medicine, Case Western Reserve University/MetroHealth Medical Center Campus, Cleveland, OH, USA.

The Cochrane Database of Systematic Reviews
|September 20, 2013
PubMed
Summary
This summary is machine-generated.

Coenzyme Q10 (CoQ10) supplementation shows no clear benefit for heart failure patients, as current trials lack clinical endpoint data. Further research is needed to determine CoQ10

More Related Videos

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Related Experiment Videos

Last Updated: May 7, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Area of Science:

  • Cardiology
  • Nutritional Science
  • Biochemistry

Background:

  • Coenzyme Q10 (ubiquinone) is a vital mitochondrial electron carrier and coenzyme.
  • CoQ10 deficiency is linked to heart failure severity and increased oxidative stress.
  • CoQ10's antioxidant and potential ion channel stabilizing properties suggest therapeutic value.

Purpose of the Study:

  • To systematically review the safety and efficacy of coenzyme Q10 in heart failure patients.
  • To analyze existing randomized controlled trials (RCTs) on CoQ10 for heart failure.

Main Methods:

  • Comprehensive literature search across multiple databases (CENTRAL, MEDLINE, EMBASE, Web of Science, CINAHL, AMED) up to January 2013.
  • Inclusion of parallel and cross-over RCTs assessing CoQ10's effects in heart failure.
  • Independent data extraction, risk of bias assessment, and meta-analysis where feasible; narrative synthesis for heterogeneous data.

Main Results:

  • Seven small studies with 914 participants compared CoQ10 to placebo; no data on clinical events were available.
  • Meta-analysis showed no clear effect on left ventricular ejection fraction or exercise capacity.
  • CoQ10 supplementation increased blood CoQ10 levels, but results are cautious due to study limitations and heterogeneity.

Conclusions:

  • Current evidence is insufficient to conclude on CoQ10's benefits or harms in heart failure due to lack of clinically relevant endpoints.
  • Existing data from small, heterogeneous trials focusing on physiological measures are inconclusive.
  • Re-evaluation of the need for further CoQ10 trials in heart failure is warranted pending stronger evidence.